N-(3-tert-butoxycarbonylaminopropyl)-4-cyano-4-phenylpiperidine | 186347-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(3-tert-butoxycarbonylaminopropyl)-4-cyano-4-phenylpiperidine
• 英文别名: tert-butyl N-[3-(4-cyano-4-phenylpiperidin-1-yl)propyl]carbamate
• CAS: 186347-50-2
• 化学式: C₂₀H₂₉N₃O₂
• 分子量: 343.469
• InChiKey: MFDSGCWPYIKZHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-tert-butoxycarbonylaminopropyl)-4-cyano-4-phenylpiperidine 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 1-(3-amino-propyl)-4-cyano-4-phenyl-piperidine
  参考文献：
  名称：

  Phenylacetamides as selective α-1A adrenergic receptor antagonists

  摘要：

  A novel class of potent and selective or-la receptor antagonists has been identified. The structures of these antagonists were derived from truncating the 4-aryl dihydropyridine subunit present in known alpha-1a antagonists. The design principles which led to the discovery of substituted phenylacetamides, the synthesis and SAR of key analogues, and the results of select in vitro and in vivo studies are described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00307-3
• 作为产物：
  描述：

  4-氰基-4-苯基哌啶-1-羧酸叔丁酯 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 N-(3-tert-butoxycarbonylaminopropyl)-4-cyano-4-phenylpiperidine
  参考文献：
  名称：

  Phenylacetamides as selective α-1A adrenergic receptor antagonists

  摘要：

  A novel class of potent and selective or-la receptor antagonists has been identified. The structures of these antagonists were derived from truncating the 4-aryl dihydropyridine subunit present in known alpha-1a antagonists. The design principles which led to the discovery of substituted phenylacetamides, the synthesis and SAR of key analogues, and the results of select in vitro and in vivo studies are described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00307-3

文献信息

• Alpha 1a adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05977115A1

  公开（公告）日：1999-11-02

  This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  该发明涉及某些新颖化合物及其衍生物，它们的合成以及它们作为选择性α-1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其放松富含α 1a受体亚型的平滑肌组织的能力上具有选择性，同时不会引起直立性低血压。这样的组织之一存在于尿道内膜周围。因此，这些化合物的一个用途是为患有良性前列腺增生的男性提供急性缓解，从而减少尿液流动的阻碍。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生影响的急性和慢性缓解。
• US5977115A
  申请人：——

  公开号：US5977115A

  公开（公告）日：1999-11-02
• US6274583B1
  申请人：——

  公开号：US6274583B1

  公开（公告）日：2001-08-14
• Phenylacetamides as selective α-1A adrenergic receptor antagonists
  作者：Michael A. Patane、Robert M. DiPardo、Randall C. Newton、RoseAnn P. Price、Theodore P. Broten、Raymond S.L. Chang、Richard W. Ransom、Jerry Di Salvo、Dhanapalan Nagarathnam、Carlos Forray、Charles Gluchowski、Mark G. Bock

  DOI：10.1016/s0960-894x(00)00307-3

  日期：2000.8

  A novel class of potent and selective or-la receptor antagonists has been identified. The structures of these antagonists were derived from truncating the 4-aryl dihydropyridine subunit present in known alpha-1a antagonists. The design principles which led to the discovery of substituted phenylacetamides, the synthesis and SAR of key analogues, and the results of select in vitro and in vivo studies are described. (C) 2000 Elsevier Science Ltd. All rights reserved.